Details, Fiction and Z-LEHD-fmk
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage numerous intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Major demo targets had been To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients